Over the calendar year, there was a decreasing trend in the proportion of patients treated with danazol, ranging from approximately 74% in 2011 to 45% in 2021.
← all excerpts
A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System.
1
—
—